Ascendia

As we step into the new year, the Ascendia team is more energized than ever, ready to tackle new challenges, spark innovation, and continue delivering exceptional services to our clients and partners. Today we are #thankful for our incredible team, our wonderful clients, and our reliable partners. You have all helped make 2024 a year of growth and success. We can’t wait to see what’s in store for 2025!

A developing pharmaceutical company partnered with Ascendia to improve the delivery system of an oncology drug, aiming to improve it's bioavailability and reduce pill burden on patients. Using our Emulsol? technology, our team developed liquid-filled hard capsules that not only lowered the patient daily pill intake from more than 10 pills to less than 3 pills, but also enhanced shelf life stability by enabling room temperature storage. Find more info about our EmulSol? technology here: https://bit.ly/2XyO1PD #Ascendia #EmulSol #Nanotechnology #OncologyDrugs

There is a lot of interest to develop innovative approaches using lipid and polymeric nanoparticle tech-nology for parenteral and oral #drugdelivery. These approaches can help alleviate the bottleneck new chemical entities (#NCEs) are causing in drug bioavailability. One result is that it has become difficult to identify the appropriate ingredi-ents or excipients to improve drug solubility and bioavailability. Ascendia? Pharmaceuticals takes a three-pronged, tailored formulation approach to address these challenges: Step One: Find the right excipients, polymers, and solvent by screening molecules for maximum solubil-ity. Step Two: Employ Ascendia’s proprietary platform nanotech-nologies – LipidSol?, NanoSol?, EmulSol?, and AmorSol? – to identify the optimal tech-nology for drug loading and stability. Step Three: Optimize the formulation by using design of experiments (DOEs) and utilizing intrinsic properties of the com-pounds. These steps help Ascendia’s scientists discover the best formulations with en-hanced efficacy and stability. Ascendia’s core capabilities in formulation and analytical development, stability and microbial testing, coupled with #cGMP manufacturing suites for sterile and non-sterile drugs, offer unparalleled benefits for expediting drug molecules faster to clinic. Learn more by visiting www.ascendiapharma.com. #LNPs #pharma #biologics

Ascendia? Pharmaceuticals is thrilled to announce that John Vrettos, PhD, has joined our team as Director, Formulation and Project Management! A member of the senior leadership team, John will be the project manager for Ascendia’s R&D and GxP projects. A 20-year industry veteran, John has previously held leadership positions with large and small companies in the #pharma and #biopharma industry. He has earned multiple patents, has been published 20 times, and has been an invited speaker/presenter on 39 occasions. Learn more about Ascendia by visiting www.ascendapharma.com. #CDMO #drugdevelopment

A major obstacle in commercial development and manufacture of #pharmaceutical products is drug instability. #Lyophilization, or #freezedrying, is a solution because it eliminates the need for cold storage or sub-zero temperatures, for more efficient storage and transportation. Lyophilization can also improve solubility of poorly soluble molecules by amorphous solid dispersions (ASD). Ascendia has a state-of-the-art #cGMP clean room lyophilizer. Our scientists use the equipment to perform freeze drying to develop sterile drug products. Coupled with our proprietary enabling nanotechnologies - AmorSol?, EmulSol?, NanoSol? and LipidSol? - Ascendia has improved the stability and solubility of small and large molecules to enhance the shelf life and bioavailability of life-saving medicines. Contact us to learn more about our tailored approach that can help your #drugdevelopment project. www.ascendiapharma.com. #LNPs #lipidnanoparticles #cdmo

Ascendia sees many #drug compounds in need of dose form optimization. Our proprietary nanotechnologies, such as NanoSol?, make this possible. Our nanotechnologies, scientific expertise, and state-of-the-art milling equipment by NETZSCH Group can breathe new life into mature drug products. Ascendia is the perfect partner for developing new compounds into drugs suitable for human use, allowing for a much faster and cost-effective development process. Additionally, drugs that are already on the market in one dose form can be transformed into new, improved dose formulations. Contact us to learn more: https://lnkd.in/eRQV_-5G #cdmo #drugdevelopment #pharma

Ascendia is excited to be attending the 2024 PODD: Partnership Opportunities in Drug Delivery Community News Conference today and tomorrow in Boston, MA! ? Stop by tabletop exhibit #101 to speak with the Ascendia team, Jim Jingjun Huang, Ph.D., Shaukat Ali and Robert Bloder, to learn more about how we can be your Partner of Choice for your?complex?drug delivery projects. Also, make sure to attend?Dr. Ali’s presentation, Lipid Nanoparticles – Carriers for Biologics and Nucleic Acids, at?today?6PM ET. We look forward to seeing you today and tomorrow! ? #Ascendia #PODD2024

Dr. Dale Eric Wurster, Professor of Pharmaceutics – College of Pharmacy at the University of Iowa, who received the 2024 AAPS Distinguished Service Award, one of the highest AAPS awards, visited the Ascendia booth during #AAPS2024.?He met with Dr. Shaukat Ali, who received AAPS fellow status last year, Ascendia Chief Business Officer Robert Bloder, and Jared Hahn, Sr. Director of Business Development for Ascendia. ' Ascendia congratulates Dr. Wurster for his achievements and his many career accomplishments. #drugdevelopment #cdmo #pharmaceuticals

Beside traditional liposomes, lipids in lipid nanoparticles (LNPs) tethered with polyethylene glycols (PEGs) can improve longer circulation and maintain the release over an extended period. Immunogenic LNPs conjugated with antibodies or proteins are designed to target the diseased tissues or conditions. Lipid assemblies comprised of lamellar and non-lamellar structures with different lipids and polymers and surfactants compositions are classified as solid #LNPs and nanostructured lipid carriers, and cubosomes, which have been used in delivery of small and large molecules orally and parenterally. Lipoplexes comprised of helper and cationic lipids have been used for encapsulating by complexing/stabilizing, and delivery of negatively charged nucleic acids (e.g. #mRNA, siRNA and #pDNA). If you are working on LNP projects, contact Ascendia. We are expert in LNPs and have proven to bring value to your LNP #drugdevelopment: https://lnkd.in/eRQV_-5G #cdmo #pharma

We are a few days away from the #AAPS 2024 PharmSci 360 Conference in Salt Lake City, UT, hosted by American Association of Pharmaceutical Scientists (AAPS) | @aapscomms! Learn more about the conference and register here: https://lnkd.in/d6F2Jb2 Don't forget to stop by Booth #2407 to discuss how Ascendia can be your Partner of Choice for your next #drugdevelopment projects. Our nano-particle technologies and expertise can provide you with complete CDMO services from pre-formulation to clinical manufacturing. Schedule a meeting here: https://lnkd.in/eRQV_-5G #Ascendia #Pharma #CDMO #PharmSci360